Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study
| Autor: | Eva Wolf, Anja Neumann, Frederik Valbert, Stefan Preis, Knud Schewe, Nikola Hanhoff, Christian Hoffmann, Kathrin Pahmeier, Stephan Klauke, Jürgen Wasem |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-HIV Agents Total cost MEDLINE HIV Infections Drug Costs 03 medical and health sciences 0302 clinical medicine Acquired immunodeficiency syndrome (AIDS) Germany Health care Humans Medicine Prospective Studies 030212 general & internal medicine Estimation business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health Health Care Costs Wirtschaftswissenschaften medicine.disease Cost driver Family medicine Cohort Female 0305 other medical science business Cohort study |
| Zdroj: | Value in Health. 23:1324-1331 |
| ISSN: | 1098-3015 |
| Popis: | Objectives The purpose of the prospective clinical and pharmacoeconomic outcomes study of different first-line antiretroviral treatment strategies (PROPHET) was to examine the healthcare costs of human immunodeficiency virus (HIV)–infected persons in Germany treated with different antiretroviral therapy (ART) strategies and to identify variables associated with high costs. Methods The setting was a 24-month prospective multicenter observational cohort study in a German HIV-specialized care setting from 2014 to 2017. A microcosting approach was used for the estimation of healthcare costs. Data were obtained via electronic case report forms. The costs were calculated from both the societal and the statutory health insurance perspective. Regression models were performed that took into consideration the impact of several independent variables. Results Four hundred thirty-four patients from 24 centers throughout Germany were included. Average annual healthcare costs were €20 118 (standard deviation [SD] €6451) per patient from the societal perspective (n = 336) and €17 306 (SD €4106) from the statutory health insurance perspective (n = 292). Expenditures for the ART medication had the highest impact. Total costs declined in the second year of therapy. There was a significant association between the amount of total cost and clinical or therapeutic variables from both perspectives; a diagnosis of acquired immune deficiency syndrome (AIDS) led to higher costs as well as the chosen ART strategy. Age also increased cost from the statutory health insurance perspective. Conclusions The main cost driver of the healthcare costs for HIV-positive patients was antiretroviral drug expenses. Further variables that influenced the costs were identified. The results provide a detailed overview of the resource use of patients in the PROPHET cohort. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect